KRMD

+ Watchlist + Portfolio

KORU Medical Systems, Inc.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.02
52-Week Range: $2.86 – $6.61
Market Cap: $136.67M
P/E (TTM): —
EPS (TTM): -0.04
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 7.57
PEG Ratio: —
Return on Equity: -10.52%
Return on Assets: -3.86%
Gross Margin: 62.43%
Operating Margin: 5.21%
Profit Margin: -4.03%
Current Ratio: 2.72
Debt/Equity: 0.18
Total Debt: $3.31M
Free Cash Flow: $725.83K
Revenue Growth: 18.20%
Earnings Growth: —
Enterprise Value: $131.69M

KRMD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$27.90M	$28.52M	$33.65M	$41.13M
Cost of Revenue	$12.53M	$11.81M	$12.31M	$15.52M
Gross Profit	$15.37M	$16.71M	$21.33M	$25.60M
Research & Development	$4.96M	$5.74M	$5.26M	$4.39M
Selling, General & Admin	$20.61M	$20.37M	$21.63M	$23.38M
Operating Expenses	$26.15M	$26.98M	$27.78M	$28.58M
Operating Income	-$10.78M	-$10.27M	-$6.45M	-$2.97M
EBITDA	-$10.19M	-$9.40M	-$5.56M	-$2.16M
Pretax Income	-$10.68M	-$9.77M	-$6.06M	-$2.62M
Income Tax	-$2.01M	$3.97M	$2.89K	$21.89K
Net Income	-$8.66M	-$13.74M	-$6.07M	-$2.64M
Diluted EPS	-0.19	-0.30	-0.13	-0.06
Diluted Shares	45.00M	45.60M	45.80M	46.19M

KRMD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$17.41M	$11.48M	$9.58M	$8.87M
Receivables	$4.53M	$4.07M	$6.00M	$6.53M
Inventory	$6.40M	$3.48M	$2.80M	$3.68M
Current Assets	$29.80M	$20.26M	$19.13M	$19.99M
Total Assets	$42.33M	$28.46M	$27.22M	$28.20M
Current Liabilities	$6.96M	$4.45M	$7.20M	$8.19M
Total Debt	$4.93M	$4.45M	$3.99M	$3.50M
Total Liabilities	$11.01M	$8.11M	$10.40M	$11.15M
Retained Earnings	-$9.57M	-$23.31M	-$29.38M	-$32.02M
Shareholders' Equity	$31.33M	$20.35M	$16.81M	$17.05M
Working Capital	$22.84M	$15.80M	$11.93M	$11.79M

KRMD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$5.40M	-$4.89M	-$319.72K	$462.40K
Capital Expenditure	-$2.80M	-$814.60K	-$1.34M	-$956.49K
Free Cash Flow	-$8.21M	-$5.71M	-$1.66M	-$494.08K
Depreciation & Amortisation	$587.14K	$870.39K	$888.47K	$810.50K
Stock-Based Compensation	$3.08M	$2.77M	$2.62M	$2.71M
Investing Cash Flow	-$2.80M	-$814.60K	-$1.33M	-$949.79K
Financing Cash Flow	$279.49K	-$218.87K	-$248.53K	-$221.35K
Net Change in Cash	-$7.93M	-$5.93M	-$1.90M	-$708.74K

KRMD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$9.64M	$10.19M	$10.40M	$10.90M	$11.76M	$12.05M
Cost of Revenue	$3.59M	$3.72M	$4.14M	$4.08M	$4.53M	$4.20M
Gross Profit	$6.05M	$6.48M	$6.26M	$6.82M	$7.23M	$7.85M
Research & Development	$1.11M	$1.19M	$933.11K	$1.14M	$1.32M	$1.07M
Selling, General & Admin	$5.96M	$5.38M	$5.99M	$6.04M	$6.58M	$5.94M
Operating Expenses	$7.29M	$6.79M	$7.13M	$7.36M	$8.10M	$7.22M
Operating Income	-$1.25M	-$312.65K	-$867.68K	-$547.10K	-$864.92K	$626.99K
EBITDA	-$1.03M	-$103.17K	-$663.20K	-$367.93K	-$667.39K	$837.02K
Pretax Income	-$1.17M	-$189.51K	-$778.12K	-$482.17K	-$807.08K	$258.25K
Income Tax	$0.00	$17.36K	-$150.00	$4.68K	$0.00	$5.80K
Net Income	-$1.17M	-$206.87K	-$777.97K	-$486.86K	-$807.08K	$252.45K
Diluted EPS	-0.03	0.00	-0.02	—	-0.02	0.01
Diluted Shares	45.98M	46.19M	46.24M	—	46.36M	49.51M

KRMD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$8.74M	$8.05M	$8.46M	$8.87M	$8.77M	$8.29M
Receivables	$6.27M	$5.09M	$5.52M	$6.53M	$6.32M	$6.09M
Inventory	$3.28M	$3.95M	$4.41M	$3.68M	$4.48M	$4.51M
Current Assets	$19.00M	$17.58M	$19.42M	$19.99M	$20.59M	$19.51M
Total Assets	$27.22M	$25.52M	$27.10M	$28.20M	$28.59M	$27.96M
Current Liabilities	$7.80M	$6.05M	$7.83M	$8.19M	$8.85M	$7.18M
Total Debt	$3.73M	$3.47M	$3.67M	$3.50M	$3.37M	$3.31M
Total Liabilities	$10.87M	$8.99M	$10.64M	$11.15M	$11.67M	$9.91M
Retained Earnings	-$30.55M	-$30.75M	-$31.53M	-$32.02M	-$32.82M	-$32.57M
Shareholders' Equity	$16.35M	$16.53M	$16.46M	$17.05M	$16.92M	$18.05M
Working Capital	$11.20M	$11.53M	$11.59M	$11.79M	$11.74M	$12.33M

KRMD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$237.47K	-$460.34K	$65.46K	$1.09M	$14.66K	$216.11K
Capital Expenditure	-$446.84K	-$28.81K	-$52.48K	-$428.36K	-$89.89K	-$577.37K
Free Cash Flow	-$684.30K	-$489.15K	$12.97K	$666.40K	-$75.22K	-$361.25K
Depreciation & Amortisation	$217.36K	$209.49K	$204.48K	$179.17K	$197.53K	$210.03K
Stock-Based Compensation	$697.59K	$415.74K	$627.39K	$972.81K	$681.51K	$457.77K
Investing Cash Flow	-$446.84K	-$28.81K	-$52.48K	-$421.65K	-$89.89K	-$577.37K
Financing Cash Flow	-$160.81K	-$191.96K	$396.33K	-$264.91K	-$29.22K	-$118.82K
Net Change in Cash	-$845.11K	-$681.12K	$409.30K	$408.19K	-$104.44K	-$480.07K

Market Snapshot

About

KORU Medical Systems develops and commercializes innovative and patient-centric subcutaneous drug delivery systems. The company's flagship product, the Freedom System, is a wearable infusion pump that enables patients to self-administer immunoglobulin therapy at home. KORU's technology improves patient quality of life by providing convenient alternatives to hospital-based infusion treatments.